NR3C2 and obstructive sleep apnea syndrome: Spironolactone (a mineralocorticoid receptor antagonist) has been proposed has a very useful tool in cases of resistant HT (Ziegler et al., 2011a,b), a very prevalent condition in OSA patients (Oliveras and Schmieder, 2013; Solini and Ruilope, 2013) in which aldosterone levels are generally elevated, as well as for severe OSA patients (Ziegler et al., 2011a).